Darmiyan

Darmiyan is a healthcare technology company focused on the early detection and diagnosis of neurodegenerative diseases, particularly Alzheimer's disease and dementia.

Founded in 2014 and based in San Francisco, California, with an office in Toronto, Canada, Darmiyan aims to illuminate brain health long before clinical signs of memory loss appear. The company is led by Padideh Kamali-Zare, PhD, and has received significant funding from industry leaders, along with patents for its innovative technology, BrainSee. BrainSee is the first FDA-approved medical software designed to assist physicians in evaluating the prognosis of patients with amnestic mild cognitive impairment (aMCI). It integrates standard clinical brain MRIs with cognitive test scores to provide a prognostic score that helps predict the likelihood of progression to Alzheimer's dementia. Darmiyan's technology is non-invasive and utilizes advanced AI for high accuracy in detecting abnormalities at a cellular level. The company also offers services for clinical prognostication, clinical trial support, and patient monitoring, aiming to improve outcomes in the field of neurology.